Academic Profile : Faculty

YiChen Lee.png picture
Dr Yi-Chen Lee (李逸蓁)
Associate Professor (Practice), School of Biological Sciences
Dr Yi-Chen Lee is Associate Professor in Practice appointed jointly by Nanyang Business School and School of Biological Sciences, PhD in Biology and Immunology from the University of Heidelberg, Germany.
Her career spans diverse sectors, including the Pharma/Biotech industry, venture capital, and digital healthcare startups. In her advisory capacity, she offers her insights to technology ventures, aiding them in navigating critical areas such as product development, regulatory compliance, and the formulation of effective funding strategies. Armed with academic foundation and industry exposure, she remains committed to bridging the gap between academic knowledge and practical applications. Her passion lies in contributing her interdisciplinary expertise to the various domains she engages with.
Her research encompasses a broad spectrum of healthcare initiatives, with a particular focus on developing Point-of-Care and digital health solutions tailored to address the complexities of chronic conditions and the unique challenges presented by an aging population.
1) Ultrasensitive Biomarker Detection for Critical Neurodegenerative Conditions at Point-of-Care:
Point-of-care (POC) solutions are pivotal in the realms of personalized and precision medicine. Leveraging cutting-edge protein detection technology utilizing optical fibers, our focus lies in projects centered around the detection of trivial amount biomarkers associated with neurodegenerative conditions. The aim should be to screen the potential patients in early stages for medical intervention and management.
2) Digital Biomarkers and Data Analytics for Chronic Conditions:
In the management of chronic diseases, the routine collection and analysis of physical biomarkers have been essential. However, with the advent of digital technologies, the capability to gather digital biomarkers, empowering patients further in their healthcare journey. The integration of both physical and digital biomarkers has emerged as the prevailing approach in chronic disease management. FemTech, which focuses on female health, presents significant market potential. The major research would focus on female unmet medical needs like menopause related syndromes.
 
  • Digital health solution for chronic diseases with biomarker detection: early screening and monitoring with economic impacts
Courses Taught
BS3202 Commercialization of Molecular and Cellular Biology Techniques
BS3203 Reshaping Healthcare with Engineering and Digital Revolution
BU5704 Bio-entrepreneurship